IFNA17 and coronary artery disorder: In our study, 43% of the CHD patients underwent treatment with pegylated IFN-α, although only 17% of IFN-α treated HDV patients showed a sustained response (HH-CHD8, HH-CHD26, HH-CHD42, Supplementary Table 3).